The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug ...
The risk for HCQ-associated retinopathy increases over time among patients with rheumatic diseases, particularly at higher doses and with prolonged exposure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results